In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus

mAbs

Volumn 2, Issue 3, 2010, Pages 335-346

  Vugmeyster, Yulia ^a   Guay, Heath ^a   Szklut, Pamela ^a   Qian, Ming D ^a   Jin, Macy ^a   Widom, Angela ^a   Spaulding, Vikki ^a   Bennett, Frann ^a   Lowe, Leslie ^a   Andreyeva, Tatyana ^a   Lowe, David ^b   Lane, Steven ^b   Thom, George ^b   Valge Archer, Viia ^b   Gill, Davinder ^a   Young, Deborah ^a   Bloom, Laird ^a  

^a PFIZER INC   (United States)

^b MEDIMMUNE   (United States)

Author keywords

Affinity maturation; Antiproduct antibodies; Autoimmunity; IL 21; IL 21R; Lupus; Monoclonal antibody; Phage display; Pharmacokinetics

Indexed keywords

IMMUNOGLOBULIN G; INTERLEUKIN 21 RECEPTOR; RECOMBINANT ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; IN VITRO STUDY; LUPUS VULGARIS; MOUSE; NONHUMAN;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; CELLS, CULTURED; COMPLEMENTARITY DETERMINING REGIONS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACACA FASCICULARIS; MALE; MICE; MICE, INBRED MRL LPR; MICE, INBRED STRAINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, INTERLEUKIN-21;

EID: 77953656147     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.3.11850     Document Type: Article

References (31)

1. Strand V, Kimberly R, Isaacs JD. Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 2007; 6:75-92. (Pubitemid 46020288)
2. Carter PJ. Potent antibody therapeutics by design. Nat Rev Immunol 2006; 6:343-357
3. Lonberg N. Fully human antibodies from transgenic mouse and phage display platforms. Curr Opin Immunol 2008; 20:450-459
4. Parrish-Novak J, Dillon SR, Nelson A, Hammond A, Sprecher C, Gross JA, et al. Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 2000; 408:57-63.
5. FH) cells in normal and dysregulated immune responses. Annu Rev Immunol 2008; 26:741-766
6. Vogelzang A, McGuire HM, Yu D, Sprent J, Mackay CR, King C. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity 2008; 29:127-137
7. Odegard JM, Marks BR, DiPlacido LD, Poholek AC, Kono DH, Dong C, et al. ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med 2008; 205:2873-2886
8. Jin H, Carrio R, Yu A, Malek TR. Distinct activation signals determine whether IL-21 induces B cell costimulation, growth arrest or Bim-dependent apoptosis. J Immunol 2004; 173:657-665 (Pubitemid 38797396)
9. Ozaki K, Kikly K, Michalovich D, Young PR, Leonard WJ. Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA 2000; 97:11439-11444
10. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 2008; 26:57-79. (Pubitemid 351600371)
11. Distler JH, Jungel A, Kowal-Bielecka O, Michel BA, Gay RE, Sprott H, et al. Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 2005; 52:856-864 (Pubitemid 40365109)
12. Jungel A, Distler JH, Kurowska-Stolarska M, Seemayer CA, Seibl R, Forster A, et al. Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 2004; 50:1468-1476 (Pubitemid 38608068)
13. Li J, Shen W, Kong K, Liu Z. Interleukin-21 induces T-cell activation and proinflammatory cytokine secretion in rheumatoid arthritis. Scand J Immunol 2006; 64:515-522 (Pubitemid 44536336)
14. Ettinger R, Kuchen S, Lipsky PE. Interleukin 21 as a target of intervention in autoimmune disease. Ann Rheum Dis 2008; 67:83-86
15. Caruso R, Fina D, Peluso I, Stolfi C, Fantini MC, Gioia V, et al. A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells. Gastroenterology 2007; 132:166-175 (Pubitemid 46108732)
16. Fina D, Sarra M, Caruso R, Del Vecchio Blanco G, Pallone F, MacDonald TT, et al. Interleukin 21 contributes to the mucosal T helper cell type 1 response in coeliac disease. Gut 2008; 57:887-892 (Pubitemid 351919521)
17. Bubier JA, Bennett SM, Sproule TJ, Lyons BL, Olland S, Young DA, et al. Treatment of BXSB-Yaa mice with IL-21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann N Y Acad Sci 2007; 1110:590-601. (Pubitemid 350043049)
18. Herber D, Brown TP, Liang S, Young DA, Collins M, Dunussi-Joannopoulos K. IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R.Fc reduces disease progression. J Immunol 2007; 178:3822-3830 (Pubitemid 46417651)
19. Young DA, Hegen M, Ma HL, Whitters MJ, Albert LM, Lowe L, et al. Blockade of the interleukin-21/interleukin-21 receptor pathway ameliorates disease in animal models of rheumatoid arthritis. Arthritis Rheum 2007; 56:1152-1163 (Pubitemid 46608640)
20. Fina D, Sarra M, Fantini MC, Rizzo A, Caruso R, Caprioli F, et al. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 2008; 134:1038-1048 (Pubitemid 351451986)
21. Kasaian MT, Tan XY, Jin M, Fitz L, Marquette K, Wood N, et al. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys. J Pharmacol Exp Ther 2008; 325:882-892 (Pubitemid 351724334)
22. Dixon FJ, Andrews BS, Eisenberg RA, McConahey PJ, Theofilopoulos AN, Wilson CB. Etiology and pathogenesis of a spontaneous lupus-like syndrome in mice. Arthritis Rheum 1978; 21:64-67
23. Reilly CM, Gilkeson GS. Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. Immunol Res 2002; 25:143-153
24. Bondensgaard K, Breinholt J, Madsen D, Omkvist DH, Kang L, Worsaae A, et al. The existence of multiple conformers of interleukin-21 directs engineering of a superpotent analogue. J Biol Chem 2007; 282:23326-23336 (Pubitemid 47311917)
25. Zhang JL, Foster D, Sebald W. Human IL-21 and IL-4 bind to partially overlapping epitopes of common gamma-chain. Biochem Biophys Res Commun 2003; 300:291-296 (Pubitemid 38375808)
26. Ozaki K, Spolski R, Feng CG, Qi CF, Cheng J, Sher A, et al. A critical role for IL-21 in regulating immunoglobulin production. Science 2002; 298:1630-1634 (Pubitemid 35387203)
27. Zhou J, Pop LM, Ghetie V. Hypercatabolism of IgG in mice with lupus-like syndrome. Lupus 2005; 14:458-466 (Pubitemid 40961320)
28. Lloyd C, Lowe D, Edwards B, Welsh F, Dilks T, Hardman C, et al. Modelling the human immune response: performance of a 1,011 human antibody repertoire against a broad panel of therapeutically relevant antigens. Protein Eng Des Sel 2009; 22:159-168
29. Griffiths AD, Williams SC, Hartley O, Tomlinson IM, Waterhouse P, Crosby WL, et al. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J 1994; 13:3245-3260 (Pubitemid 24226939)
30. Hawkins RE, Russell SJ, Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 1992; 226:889-896
31. Cummins E, Luxenberg DP, McAleese F, Widom A, Fennell BJ, Darmanin-Sheehan A, et al. A simple high-throughput purification method for hit identification in protein screening. J Immunol Methods 2008; 339:38-46.